• Recent Publications

• Review Articles

1.Tang DG, Tian HS.  Interleukin-2 (IL-2) production by the splenocytes of C57BL/6 mice bearing Lewis lung carcinoma is markedly inhibited by endogenous prostaglandin E2 (PGE2).  J. Exp Clin Immunol. 5:12-13, 1989.

2.Tang DG, Tian HS.  Inhibitory effects of prostaglandin E1 (PGE1) and indomethacin on the growth and metastasis of transplanted Lewis lung carcinoma in C57BL/6 mice.  Chin. Med. J. (Engl) 103:208-215, 1990.

3.Chen Y, Gao X, Timar J, Tang DG, Grossi IM, Chelladurai M, Kunicki TJ, Fligiel SEG, Taylor JD, Honn KV.  Identification of the aIIbb3 integrin in murine tumor cells.  J. Biol. Chem. 267:17314-17320, 1992.

4.Wojtukiewicz MZ, Tang DG, Nelson KK, Walz DA, Diglio CA, Honn KV.  Thrombin enhances tumor cell adhesive and metastatic properties via increased aIIbb3 expression on the cell surface.  Thromb. Res. 68:233-245, 1992.

5.Steinert BW, Tang DG, Jones CL, Grossi IM, Umbarger LA, Honn KV.  Studies on the role of platelet eicosanoid metabolism and integrin aIIbb3 in tumor cell induced platelet aggregation.  Int. J. Cancer 54:92-101, 1993.

6.Wojtukiewicz MZ, Tang DG, Ciarelli JJ, Nelson KK, Walz DA, Diglio CA, Mammen EF, Honn KV.  Thrombin increases the metastatic potential of tumor cells via protein kinase C signal transduction pathway.  Int J. Cancer 54:793-806, 1993.

7.Timar J, Tang DG, Bazaz R, Rong X, Kimler V, Taylor JD, Honn KV.  12(S)-HETE induces the rearrangement of tumor cell cytoskeleton by PKC-dependent mechanism.  Cell Motil. & Cytoskel. 26:49-65, 1993.

8.Tang DG, Timar J, Grossi IM, Renaud C, Kimler V, Diglio CA, Taylor JD, Honn KV.  The lipoxygenase metabolite, 12(S)-HETE, induces a protein kinase C dependent cytoskeletal rearrangement and retraction of microvascular endothelial cell.  Exp. Cell Res. 207:361-375, 1993.

9.Tang DG, Chen Y, Diglio CA, Honn KV.  PKC-dependent effects of 12(S)-HETE on endothelial cell vitronectin and fibronectin receptor.   J. Cell Biol. 121:689-704, 1993.

10.Tang DG, Chen Y, Newman PJ, Shi L, Gao X, Diglio CA, Honn KV.  Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium.  J. Biol Chem. 268:22883-22894, 1993.

11.Tang DG, Grossi IM, Diglio CA, Honn KV.  12(S)-HETE promotes tumor cell adhesion by increasing surface expression of avb3 integrins on endothelial cells.  Int. J. Cancer 54:102-111, 1993.

12.Tang DG, Diglio CA, Honn KV.  12(S)-HETE-induced microvascular endothelial cell retraction results from PKC-dependent rearrangement of cytoskeletal elements and avb3 integrin.  Prostaglandins 45:249-268, 1993.

13.Tang DG, Onoda JM, Grossi IM, Nelson KK, Umbarger L, Honn KV. Phenotypic properties of tumor cells in culture: aIIbb3 integrin expression, tumor cell induced platelet aggregation, and tumor cell adhesion to endothelium as important parameters of metastatic potential.  Int. J. Cancer 54:338-347, 1993.

14.Honn KV, Tang DG, Grossi IM, Renaud C, Diglio CA.  Enhanced endothelial cell retraction mediated by 12(S)-HETE: A proposed mechanism for the role of platelets in tumor cell metastasis.  Exp. Cell Res. 210:1-9, 1994.

15.Honn KV, Tang DG, Duniec ZM, Grossi IM, Timar J, Renaud C, Leithauser M, Blair I, Diglio CA, Kimler VA, Taylor JD, Marnett LJ.  Tumor cell-derived 12(S)-hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction.  Cancer Res. 54:565-574, 1994.

16.Tang DG, Diglio CA, Honn KV.  Activation of microvascular endothelium by 12(S)-HETE leads to enhanced tumor cell adhesion via upregulation of surface expression of avb3 integrin: A post-transcriptional, PKC- and cytoskeleton-dependent process.  Cancer Res. 54:1119-1129, 1994.

17.Tang DG, Grossi IM, Tang KQ, Honn KV. Inhibition of TPA and 12(S)-HETE-stimulated tumor-cell adhesion by prostacyclin and its stable analogs – Rationale for their antimetastatic effects.  Int. J. Cancer 60:418-425, 1995.

18.Wojtukiewicz MZ, Tang DG, Ben-Josef E, Walz DA, Honn KV.  Solid tumor cells express functional “tethered ligand” thrombin receptor. Cancer Res. 55:698-704, 1995.

19.Timar J, Bazaz R, Tang DG, Kimler V, Robertson D, Taylor JD, Honn KV.  Immunomorphological characterization and effects of 12(S)-HETE on a dynamic intracellular pool of the aIIbb3-integrin in melanoma cells.  J. Cell Sci. 108:2175-2186, 1995.

20.Tang DG, Diglio CA, Honn KV. Transcriptional activation of integrin av in microvascular endothelial cells by PKC activator 12(S)-HETE. J. Cell Sci., 108: 2629-2644, 1995.

21.Tang DG, Renaud C, Stojakovic S, Diglio CA, Porter A, Honn KV.  12(S)-HETE is a mitogenic factor for microvascular endothelial cells: Its potential role in angiogenesis.  Biochem. Biophys. Res. Commun. 211:462-468, 1995.

22.Tang DG, Tarrien M, Dobrzynski P, Honn KV.  Melanoma cell spreading on fibronectin induced by 12(S)-HETE involves both PKC- and protein tyrosine kinase-dependent focal adhesion formation and tyrosine phosphorylation of focal adhesion kinase (pp125FAK).  J. Cell Physiol. 165:291-306, 1995.

23.Tang DG, Chen YQ, Honn KV.  Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis.  Proc. Natl. Acad. Sci. USA 93:5241-5246, 1996.

24.Tang DG, Diglio CA, Honn KV.  Tyrosine phosphorylation of a ~30 kd protein precedes b3 integrin mediated microvascular endothelial cell spreading and motility on extracellular matrix proteins.  Pathol. Oncol. Res. 2:21-29, 1996.

25.Tang DG, Honn KV.  Apoptosis of W256 carcinosarcoma cells of the monocytoid origin induced by NDGA involves lipid peroxidation and depletion of GSH: Role of 12-lipoxygenase in regulating tumor cell survival.  J. Cell. Physiol. 172:155-170, 1997.

26.Tang DG, Guan K-L, Li L, Honn KV, Chen YQ, Rice RL, Taylor JD, Porter AT.  Suppression of W256 carcinosarcoma cell apoptosis by arachidonic acid and other unsaturated fatty acids.  Int. J. Cancer 72:1078-1087, 1997.

27.Rice R, Tang DG, Haddad M, Honn KV, Taylor JD.  12(S)-hydroxyeicosatetraenoic acid increases the actin microfilament content in B16a melanoma cells: A protein kinase-dependent process.  Int. J. Cancer 77:271-278, 1998.

28.Tang DG, Li L, Chopra D, Porter AT.  Extended survivability of prostate cancer cells in the absence of trophic factors: Increased proliferation, evasion of apoptosis and the role of apoptosis proteins.  Cancer Res. 58:3466-3479, 1998.

29.Tang DG, Li L, Zhu Z, Joshi B.  Apoptosis in the absence of cytochrome c accumulation in the cytosol.  Biochem. Biophys. Res. Commun. 242:380-384, 1998.

30.Rice RL, Tang DG, Taylor JD.  Actin cleavage in various tumor cells is not a critical requirement for executing apoptosis.  Pathol. Oncol. Res. 4:135-145, 1998.

31.Tang DG, Li L, Zhu Z, Joshi B, Johnson CR, Marnett LJ, Honn KV, Crissman JD, Krajewski S, Reed JC, Timar J, Porter AT.  BMD188, a novel hydroxamic acid compound demonstrates potent anti-prostate cancer effects in vitro and in vivo: Requirements for mitochondria, reactive oxygen species, and proteases.  Pathol. Oncol. Res. 4:179-190, 1998.

32.Garde S, Basrur V, Li L, Finkelman M, Krishan A, Ben-Josef E, Haddad M, Taylor JD, Porter AT, Tang DG.  Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell (PC3) in vitro and in vivo by inducing apoptosis.  Prostate 38:118-125, 1999.

33.Ben-Josef E, Yang S-Y, Tae HJ, Bidart JM, Garde SV, Chopra D, Porter AT, Tang DG. Hormone-refractory prostate cancer cells express functional follicular-stimulating hormone receptor (FSHR).  J. Urol. 161:970-976, 1999.

34.Li L, Zhu Z, Joshi B, Porter AT, Tang DG.  A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.  Anticancer Res. 19:51-60, 1999.

35.Li L, Zhu Z, Joshi B, Zhang C, Johnson CR, Marnett LJ, Honn KV, Crissman JD, Porter AT, Tang DG.  A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. II: In vivo efficacy and pharmacokinetic studies.  Anticancer Res. 19:61-70, 1999.

36.Ren W-P, Tang DG.  The extracts of Solanum Muricatum (Pepino/CSG) inhibits tumor growth through inducing apoptosis.  Anticancer Res. 19:403-408, 1999.

37.Joshi B, Li L, Taffe BG, Zhu Z, Ben-Josef E, Taylor JD, Porter AT, Tang DG.  Apoptosis induction by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain.  Cancer Res. 59:4343-4355, 1999.